Revised forecast
Fiscal year ending March 2026Administration to the final patient was not completed by the end of March 2026 because patient enrollment was suspended during the period in which the reagents and other materials used for quality testing were reviewed and changes were made following consultations with the PMDA.
| Item | Details |
|---|---|
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Reason for the revision | Administration to the final patient was not completed by the end of March 2026 because patient enrollment was suspended during the period in which the reagents and other materials used for quality testing were reviewed and changes were made following consultations with the PMDA. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company reviewed and changed the reagents and other materials used for quality testing of the cell product after manufacturing and before administration, following consultations with the PMDA. Patient enrollment was suspended during this period. Enrollment has now resumed, but administration to the final patient could not be completed by the end of March 2026.